Your Health, We Care
The New England Journal of Medicine has released the latest research on the final results of the combination of dalafenib and trametinib as adjuvant therapy for stage III melanoma.
In patients with stage III melanoma who have undergone resection, there is a better recurrence free survival and distant metastasis free survival, and the risk of death is reduced by 25% with combination therapy.
